



IlluminOss Medical to Showcase World's First Minimally Invasive Conforming Implant System at AAOS 2015

March 16, 2015

WHO: [IlluminOss Medical](#), a privately-held, commercial stage medical device company focused on minimally invasive orthopedic fracture repair. The IlluminOss System is the world's first and only system of its kind and offers significant advantages for the treatment of complex fractures.

WHAT: IlluminOss Medical will be exhibiting its technology at [AAOS 2015](#). The [IlluminOss System](#) utilizes a light-curable polymer, contained within an expandable balloon catheter, to achieve bone stabilization. The simple, percutaneous surgical approach enables surgeons to create a patient-conforming implant. In many cases it allows the patient to get back to daily activities more quickly without the hindrance of a hard cast.

[Benefits](#) observed from the use of the product in patients include smaller incisions, shorter procedure times, and more rapid post-procedure patient mobility with reduced hospital stays and lower complication rates. The small diameter of the flexible catheter gives the surgeon greater freedom of surgical approach. Once cured, the implant provides longitudinal strength and rotational stability over the length of the implant.

WHERE:

Booth #2022

Venetian/Sands Expo

Las Vegas, NV

WHEN: March 24-28, 2015

About IlluminOss

IlluminOss Medical is a privately-held, commercial stage medical device company focused on designing, developing and marketing orthopedic fracture repair products that leverage its proprietary bone stabilization technology, the IlluminOss System. This minimally invasive technology allows for fracture fixation through patient specific intramedullary implants. The system utilizes a light-curable polymer, contained within an expandable balloon catheter, to achieve bone stabilization. The revolutionary procedure is made through a small percutaneous surgical approach providing patients and clinicians with a fast, patient-specific, method of orthopedic bone stabilization. The company

currently markets its products in international countries under a CE Mark for approved clinical applications through both a direct sales force and distribution networks.

Founded in 2007, IlluminOss is headquartered in East Providence, RI, and funded by Foundation Medical Partners, New Leaf Venture Partners, Tekla Capital, Life Sciences Partners, SR One, Longwood Fund, Excel Venture Management, Pappas Ventures, Mieza Capital and Slater Technology. Learn more at www.illuminoss.com.

The IlluminOss products are Investigational Devices; limited by Federal law to Investigational Use and are not approved for sale in the USA.

Media Contact:

Jordan Bouclin

SVM Public Relations

Jordan.bouclin@sympr.com

(401)490-9700